MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$43,059,000
EPS
-$0.18
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Collaboration revenue - related party
-0 0 0
Research and development
32,003,000 28,632,000 31,164,000 40,156,000
Impairment of long-lived asset
-0 0 2,382,000
General and administrative
14,089,000 13,772,000 13,737,000 14,281,000
Total operating expenses
46,092,000 42,404,000 44,901,000 56,819,000
Loss from operations
-46,092,000 -42,404,000 -44,901,000 -56,819,000
Interest and other income, net
3,573,000 3,660,000 3,926,000 6,187,000
Interest expense
300,000 313,000 344,000 268,000
Other income (expenses), net
212,000 247,000 -81,000 -43,000
Total other income (expenses), net
3,485,000 3,594,000 3,501,000 5,876,000
Loss before income taxes
--38,810,000* --
Tax benefit at federal statutory rate
--10,021,500* --
Research tax credits
-445,750* --
Change in valuation allowance
-8,853,500* --
Stock-based compensation
-1,570,000* --
Other
-43,750* --
Other adjustments
-0* --
Income tax expense
-0* --
Net loss
-42,607,000 -38,810,000 -41,400,000 -50,943,000
Net unrealized gain (loss) on available-for-sale investments
-452,000 34,000 280,000 -88,000
Net comprehensive loss
-43,059,000 -38,776,000 -41,120,000 -51,031,000
Basic EPS
-0.18 -0.171 -0.19 -0.23
Diluted EPS
-0.18 -0.171 -0.19 -0.23
Basic Average Shares
240,290,782 226,163,829 222,038,680 218,929,548
Diluted Average Shares
240,290,782 226,163,829 222,038,680 218,929,548
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net comprehensiveloss-$43,059,000 (27.75%↑ Y/Y)Interest and otherincome, net$3,573,000 (-35.22%↓ Y/Y)Other income(expenses), net$212,000 (130.43%↑ Y/Y)Net loss-$42,607,000 (28.67%↑ Y/Y)Net unrealized gain(loss) on...-$452,000 (-442.42%↓ Y/Y)Total other income(expenses), net$3,485,000 (-36.15%↓ Y/Y)Interest expense$300,000 (100.00%↑ Y/Y)Loss from operations-$46,092,000 (29.30%↑ Y/Y)Total operatingexpenses$46,092,000 (-29.30%↓ Y/Y)Research and development$32,003,000 (-36.25%↓ Y/Y)General andadministrative$14,089,000 (-6.02%↓ Y/Y)

Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics, Inc. (ALLO)